Core Insights - Genprex Inc. shares experienced a significant increase of 41.39% to $0.36 in after-hours trading following the announcement of a conference presentation [1] Company Developments - Genprex announced that its research collaborators will present preclinical data on its lead drug candidate, "Reqorsa" Gene Therapy, at the 2025 AACR-NCI-EORTC International Conference in Boston from October 22 to October 26 [2] - CEO Ryan Confer emphasized the validation of REQORSA as a potential treatment for various cancer types, including a subset of lung cancer, and expressed anticipation for ongoing studies in combination with ALK inhibitors [3] - In October 2024, Genprex partnered with the University of Michigan Rogel Cancer Center to study TUSC2 alongside ALK-inhibitors, and collaborated with ALK Positive, a patient-led nonprofit, to co-sponsor the research [3] Research Findings - The University of Michigan Rogel Cancer Center will present a poster on October 25, showcasing lab studies that indicate tumor cells absorbed TUSC2 at levels 10 to 33 times higher than normal cells after REQORSA treatment [4] - REQORSA utilizes Genprex's Oncoprex® Delivery System, which employs non-viral lipid-based nanoparticles designed to target negatively charged cancer cells while minimizing uptake by normal tissues [4] Stock Performance - Genprex has faced a decline of 25.7% over the past year and a significant drop of 70.29% year-to-date, although the stock increased by 25.6% over the last five days [5] - The stock price has fluctuated between $0.14 and $3.97 over the past year, with a current market cap of $11.06 million and an average daily trading volume of 14.01 million shares [5] - GNPX closed regular trading on Tuesday at $0.25, reflecting a 30.15% increase [5]